Drugs / RFT5-SMPT-dgA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00025662 | May 2001 → Feb 2008 | Hodgkins lymphoma, chronic myelomonocytic leukemia, graft versus host disease, lymphoid leukemia +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RFT5-SMPT-dgA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00025662 ↗ |
| Action | Deplete | “immunotoxin, RFT5-SMPT-dgA, is added during the last 24 hours of culture to remove alloreacting cells.” NCT00025662 ↗ |
| Modality | Other / unclassified | “anti-CD25 immunotoxin” PMID 15817673 ↗ Apr 2005 |